Dergiler / Turkish Journal of Gastroenterology / 2015 / Cilt: 26 - Sayı: 6

DR-70 as a novel diagnostic biomarker for gastric cancer

Sayfa
480–483
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

The positive predictive value was 80.0%, and the negative predictive value was 82.1%.Conclusion: The DR-70 immunoassay reliably differs between gastric cancer and healthy controls, promising to become a useful cancer detection tool in clinical practice

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Background/Aims: To assess the utility of the DR-70 immunoassay in the diagnosis of gastric cancer.Materials and Methods: A total of 29 patients with histologically proven malignant gastric tumor and 29 healthy blood donors were enrolled in this study.
📊
Temel Bulgular & Veri:DR-70 immunoassay was performed using an enzyme-linked immunosorbent assay kit to quantify the serum levels of fibrin degradation products.Results: The DR-70 values in patients with gastric cancer significantly differed from the values in controls (p<0.0001).
💡
Sonuç & Katkı:The positive predictive value was 80.0%, and the negative predictive value was 82.1%.Conclusion: The DR-70 immunoassay reliably differs between gastric cancer and healthy controls, promising to become a useful cancer detection tool in clinical practice
🔬Tür:Araştırma Makalesi
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:Alan Parametreleri

Özet

Background/Aims: To assess the utility of the DR-70 immunoassay in the diagnosis of gastric cancer.Materials and Methods: A total of 29 patients with histologically proven malignant gastric tumor and 29 healthy blood donors were enrolled in this study. DR-70 immunoassay was performed using an enzyme-linked immunosorbent assay kit to quantify the serum levels of fibrin degradation products.Results: The DR-70 values in patients with gastric cancer significantly differed from the values in controls (p<0.0001). Receiver operating characteristic curve analysis revealed ≥1.45 µg/mL as the best cut-off value to distinguish between patients with gastric cancer and healthy controls. The area under the receiver operating characteristic curve was 0.871. Using ≥1.45 µg/mL as the cut-off value, the DR-70 immunoassay showed a good clinical performance with a sensitivity of 82.8% and a specificity of 79.3%. The positive predictive value was 80.0%, and the negative predictive value was 82.1%.Conclusion: The DR-70 immunoassay reliably differs between gastric cancer and healthy controls, promising to become a useful cancer detection tool in clinical practice

🔖

Bu Makaleye Atıf Yap

ARHAN, M., YILMAZ, H., ONAL, İ. K., KOCABIYIK, M., ERDAL, H., İBİŞ, M. (2015). DR-70 as a novel diagnostic biomarker for gastric cancer. Turkish Journal of Gastroenterology, Cilt: 26 - Sayı: 6, 480–483. https://ajindex.com/articles/409403

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (1)

  1. Hayes DF, Bast RC, Desch CE, et al. Tumor marker utility grading system: a framework to evaluate clinical utility of tumor markers. J Natl Cancer Inst 1996; 88: 1456-66. [CrossRef] 2. Gravalos C, Jimeno A. HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target. Ann Oncol 2008; 19: 1523-9. [CrossRef] 3. Lorenzen S, Lordick F. How will human epidermal growth factor receptor 2-neu data impact clinical management of gastric cancer? Curr Opin Oncol 2011; 23: 396-402. [CrossRef] 4. Wu D, Zhou X, Yang G, et al. Clinical performance of the AMDL DR-70 immunoassay kit for cancer detection. J Immunoassay 1998; 19: 63-72. [CrossRef] 5. Small-Howard AL, Harris H. Advantages of the AMDL-ELISA DR-70 (FDP) assay over carcinoembryonic antigen (CEA) for monitoring colorectal cancer patients. J Immunoassay Immunochem 2010; 31: 131-47. [CrossRef] 6. Kerber A, Trojan J, Herrlinger K, Zgouras D, Caspary WF, Braden B. The new DR-70 immunoassay detects cancer of the gastrointestinal tract: a validation study. Aliment Pharmacol Ther 2004; 20: 983-7. [CrossRef] 7. Li X, Qiao Z, Long X, Wei J, Cheng Y. Serum concentration of AMDL DR-70 for the diagnosis and prognosis of carcinoma of the tongue. Br J Oral Maxillofac Surg 2005; 43: 513-5. [CrossRef] 8. Lin SZ, Chen CC, Lee KC, et al. DR-70 immunoassay for the surveillance of hepatocellular carcinoma. J Gastroenterol Hepatol 2012; 27: 547-52. [CrossRef] 9. Sturgeon CM, Duffy MJ, Hofmann BR, et al. National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for use of tumor markers in liver, bladder, cervical, and gastric cancers. Clin Chem 2010; 56: 1-48. [CrossRef]